Access

The goal of this course is to demystify market access for anyone involved. You will be equipped with clear schematic overviews of the market access systems in Europe’s major markets as a resource for reference in your daily work.

This course offers a clear and structured framework for value pricing to get market access in pharma. It provides an overview of the key concepts, frameworks, and evidence-based approaches to get prices right and access delivered. Whether you are involved directly in pricing or work in a related function, this course will help you build the essential knowledge needed to contribute more effectively to pricing and market access decisions.

This course offers a practical overview of market access and its application in business development and clinical strategy decisions. You’ll gain essential knowledge of payer expectations and HTA systems in Europe, and learn how access-related data should inform strategic decision-making. Through real-world examples and interactive group work, you’ll be equipped to make access-aware decisions in business development and clinical strategy

Real World Evidence (RWE) has become an essential addition to Randomised Controlled Trials (RCTs) to further reduce regulatory, payer, physician and patient uncertainty. Unfortunately, many companies struggle implementing it. The key ingredient to success is a cross-functional organisation where managers have widespread knowledge of the fundamentals and a shared vocabulary. In this course you will learn the fundamentals of RWE so that you can contribute effectively when decisions are made and/or when implementing RWE studies.

This course offers a clear and structured framework for value pricing to get market access in pharma. It provides an overview of the key concepts, frameworks, and evidence-based approaches to get prices right and access delivered. Whether you are involved directly in pricing or work in a related function, this course will help you build the essential knowledge needed to contribute more effectively to pricing and market access decisions.

Real World Evidence (RWE) has become an essential addition to Randomised Controlled Trials (RCTs) to further reduce regulatory, payer, physician and patient uncertainty. Unfortunately, many companies struggle implementing it. The key ingredient to success is a cross-functional organisation where managers have widespread knowledge of the fundamentals and a shared vocabulary. In this course you will learn the fundamentals of RWE so that you can contribute effectively when decisions are made and/or when implementing RWE studies.

This course offers a clear and structured framework for value pricing to get market access in pharma. It provides an overview of the key concepts, frameworks, and evidence-based approaches to get prices right and access delivered. Whether you are involved directly in pricing or work in a related function, this course will help you build the essential knowledge needed to contribute more effectively to pricing and market access decisions.